How did J&J’s Imaavy perform in its warm autoimmune hemolytic anemia trial?

J&J’s FcRn blocker Imaavy achieved statistically significant and sustained red blood cell responses in its phase 2/3 Energy study for warm autoimmune hemolytic anemia. Nearly two‑thirds of patients on the 30 mg/kg dose met the primary endpoint, showing strong hemoglobin improvement and reduced steroid use, prompting an FDA priority review for potential first‑in‑class approval.